Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air Inc (NASDAQ: XAIR) is a clinical-stage medical technology company pioneering nitric oxide delivery systems for respiratory care. This news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical trial progress, and technological advancements related to the LungFit™ platform.
Access timely press releases covering FDA communications, partnership announcements, and research developments in pulmonary hypertension treatment. Our curated collection includes updates on international regulatory strategies and peer-reviewed study publications, offering critical insights into the company's position within the respiratory therapy market.
Key content categories include clinical trial results, device approval updates, executive leadership changes, and scientific conference presentations. This resource enables stakeholders to track the company's progress in developing NO-based solutions for ventilator-associated pneumonia and chronic lung conditions.
Bookmark this page for streamlined access to material developments affecting XAIR's market position. For comprehensive analysis of how these updates may influence investment decisions, consult your financial advisor and review official SEC filings.
Beyond Cancer, Ltd., an affiliate of Beyond Air (NASDAQ: XAIR), has presented new promising data at the AACR Annual Meeting 2023 supporting its ultra-high concentration nitric oxide (UNO) therapy for treating solid tumors. Key findings from in vivo studies indicate that UNO provides significant survival benefits in aggressive 4T1 breast cancer models, outperforming checkpoint inhibitors like anti-CTLA-4 and anti-PD-1. Moreover, UNO demonstrated a dose-dependent increase in mPD-L1 expression, suggesting its potential to enhance tumor sensitivity to immunotherapy. The ongoing Phase 1 study is expanding to multiple sites in Israel to diversify patient enrollment and expedite results. The data highlight the possibility of UNO as an effective treatment option with limited toxicity for difficult-to-treat cancer types.
Additional trials are anticipated throughout 2023.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
